Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | MPO | P05164 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | ICMT | O60725 | 4/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8088111 | 1.00 | HTR2A (0.60) | HTR2AMPOSLC6A4NR4A2ICMT | |
| SCHEMBL6516641 | 0.86 | HTR2A (0.58) | HTR2ASLC6A4NR4A2RIPK1GAA | |
| SCHEMBL25139842 | 0.82 | HTR2A (0.54) | HTR2ASLC6A4NR4A2RIPK1AHR | |
| SCHEMBL25139668 | 0.82 | HTR2A (0.54) | HTR2ASLC6A4NR4A2RIPK1AHR | |
| SCHEMBL3611008 | 0.81 | HTR2A (0.60) | HTR2AMPONR4A2ICMTGAA | |
| SCHEMBL32684012 | 0.81 | MPO (0.50) | MPOSLC6A4ICMTGAANPSR1 | |
| SCHEMBL1973303 | 0.81 | MPO (0.74) | HTR2AMPOSLC6A4ICMTRIPK1 | |
| SCHEMBL20588278 | 0.78 | HTR2A (0.75) | HTR2AMPOSLC6A4NR4A2RIPK1 | |
| SCHEMBL13715436 | 0.78 | HTR2A (0.65) | HTR2ASLC6A4NR4A2RIPK1AHR | |
| SCHEMBL5163846 | 0.78 | CSNK2A2 (0.50) | MPOICMTGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071243-A1 | BIOLOGICAL PRODUCTION OF TRYPTOPHAN-DERIVED PRODUCTS | UNIV TEXAS (US) | 2026-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071243-A1 | BIOLOGICAL PRODUCTION OF TRYPTOPHAN-DERIVED PRODUCTS | TPH1, TPH2, SLC6A4 | HTR2A 8/4885MPO 1194/4885SLC6A4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.